- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.01. | XOMA Royalty announces CFO transition | 11 | Seeking Alpha | ||
| 12.01. | XOMA Royalty Corporation: XOMA Royalty Announces CFO Transition | 136 | GlobeNewswire (Europe) | EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from... ► Artikel lesen | |
| 12.01. | XOMA Royalty Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 02.01. | Dividendenbekanntmachungen (02.01.2026) | 11.228 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AIR PRODUCTS & CHEMICALS INC US0091581068 1,79 USD 1,5248 EUR ALICO INC US0162301040 0,05 USD 0,0425 EUR AMERICAN COASTAL INSURANCE... ► Artikel lesen | |
| 31.12.25 | Leerink Partners reiterates Outperform rating on XOMA stock at $45 target | 2 | Investing.com | ||
| 31.12.25 | Leerink Partners bestätigt Outperform-Rating für XOMA bei Kursziel von 45 US-Dollar | 2 | Investing.com Deutsch | ||
| 30.12.25 | Takeda, XOMA ink new royalty agreement; amend existing deal | 3 | Seeking Alpha | ||
| 30.12.25 | XOMA und Takeda passen Lizenzvereinbarung an: Takeda erwirbt Mehrheit der Royalties für Mezagitamab zurück | 21 | Investing.com Deutsch | ||
| XOMA CORPORATION PREF Aktie jetzt für 0€ handeln | |||||
| 30.12.25 | Takeda regains majority of mezagitamab royalty interest from XOMA | 4 | Investing.com | ||
| 30.12.25 | XOMA Royalty Corporation: XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab | 596 | GlobeNewswire (Europe) | - Takeda regains a majority of XOMA Royalty's royalty interest in mezagitamab (TAK-079) -- XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine... ► Artikel lesen | |
| 22.12.25 | XOMA Preferred Shares Series A declares $0.5391 dividend | 2 | Seeking Alpha | ||
| 22.12.25 | XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend | 4 | Seeking Alpha | ||
| 22.12.25 | XOMA Royalty Corporation: XOMA Royalty Declares Quarterly Preferred Stock Dividends | 1 | GlobeNewswire (USA) | ||
| 16.12.25 | Xoma acquires another struggling biotech, this time zeroing in on Generation Bio | 5 | FierceBiotech | ||
| 16.12.25 | 'Zombie' biotech buyer Xoma to acquire Generation Bio | 4 | BioPharma Dive | ||
| 16.12.25 | Jefferies downgrades Generation Bio stock to Hold as XOMA acquisition announced | 1 | Investing.com | ||
| 15.12.25 | XOMA Royalty to acquire Generation Bio | 1 | Seeking Alpha | ||
| 15.12.25 | XOMA Royalty Corporation Enters into Agreement to Acquire Generation Bio Co. | 340 | GlobeNewswire (Europe) | - Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio's collaboration with Moderna - - Generation Bio's cell-targeted lipid nanoparticles (ctLNP) delivery... ► Artikel lesen | |
| 12.12.25 | XOMA stock maintains Buy rating at Benchmark despite partner's trial setback | 1 | Investing.com | ||
| 11.12.25 | Why Is XOMA Royalty Stock Sinking Thursday? | 3 | Benzinga.com |
1 2 3 4 5 Weiter >>
89 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | Diagnostikkonzern Qiagen überrascht im Schlussquartal - Weiteres Wachstum 2026 | VENLO/HILDEN (dpa-AFX) - Qiagen hat 2025 von einer anziehenden Nachfrage nach seinen Kernprodukten profitiert. Dabei lief das Schlussquartal besser als vom Labordienstleister und Diagnostikkonzern... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 64,62 | +4,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ERASCA | 12,290 | +3,45 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,960 | +11,24 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 62,19 | +0,10 % | Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns | ||
| IMMUNOVANT | 27,040 | +12,39 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 | IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 74,96 | +2,39 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 29,770 | +5,53 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| LIMINATUS PHARMA | 1,840 | -10,24 % | Liminatus Pharma, Inc. - 8-K, Current Report | ||
| DAY ONE BIOPHARMACEUTICALS | 11,410 | +8,87 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 13,980 | +7,62 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 25,360 | +1,40 % | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Das Unternehmen XOMA CORPORATION PREF kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 20,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XOMA CORPORATION PREF finden Sie auf Wallstreet Online.